Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||-0.09%||704.80||2.6%||$681.87m|
|GILD||Gilead Sciences, Inc.||0.00%||63.93||1.0%||$522.23m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.17%||291.91||1.9%||$390.67m|
|SNSS||Sunesis Pharmaceuticals, Inc.||0.00%||4.37||0.7%||$305.48m|
|SAVA||Cassava Sciences, Inc.||-0.82%||43.48||0.0%||$193.39m|
|BMRN||BioMarin Pharmaceutical, Inc.||0.00%||85.84||4.2%||$84.06m|
|NRBO||NeuroBo Pharmaceuticals, Inc.||4.20%||13.90||0.0%||$80.11m|
|EXAS||EXACT Sciences Corp.||-2.09%||33.72||17.6%||$73.25m|
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.